The Determinants of Pharmaceutical Research and Development Investments

B.E. Journal of Economic Analysis and Policy

Volumn 5, Issue 1, 2006, Pages

  Civan, Abdulkadir ^a   Maloney, Michael T ^b  

^a FATIH UNIVERSITY   (Turkey)

^b CLEMSON UNIVERSITY   (United States)

Author keywords

intellectual property; patents

Indexed keywords

EID: 64549132749     PISSN: None     EISSN: 19351682     Source Type: Journal    
DOI: 10.1515/1538-0645.1511     Document Type: Article

References (37)

1. Acemoglu, D., and Linn, J., 2004, "Market Size in Innovation: Theory and Evidence From The Pharmaceutical Industry, The Quarterly Journal of Economics, 119(3) August, 1049-1090
2. Bernt, E.R., Bui, L., Reiley, D.R. and Urban, G.L., 1995, "Information, Marketing, and Pricing in the US Antiulcer Drug Market, " American Economic Review, 85(2) May, 100-105.
3. Chin J., Grossman, G., 1990, "Intellectual Property Rights and North-South Trade, " in The Political Economy of International Trade: Essays in Honor of Robert E. Baldwin, Jones, R., and Krueger, A., eds., (Cambridge: Basil Blackwell) 90-108.
4. Cothran, C.B., 2005, "Prescription Drug Prices Based on Demand Intensity, " unpublished Master's thesis, John E. Walker Department of Economics, Clemson University.
5. Danzon, P.M., 1997, "Price Discrimination for Pharmaceuticals: Welfare Effects in the US and the EU, " International Journal of the Economics of Business, 4(3) November, 301-321.
6. Danzon, P.M., 2004, "Parallel Trade and Comparative Pricing of Medicines: Poor Choice for Patients?" PfizerForum.com: A World of Ideas on Public Policy. www.pfizerforum.com/english/danzon.shtml.
7. Danzon, P.M., Chao, L., 2000, "Cross-National Price Differences for Pharmaceuticals: How Large and Why?" Journal of Health Economics, 19(2) March, 159-195.
8. Danzon, P.M., Kethcam, J., 2003, "Reference Pricing of Pharmaceuticals for Medicare: Evidence from Germany, The Netherlands and New Zealand, " National Bureau of Economic Research Working Paper No. 10007, September (Cambridge MA: NBER).
9. Danzon, P.M., Wang, R., and Wang L, 2003, "The Impact of Price Regulation on the Launch Delay of New Drugs-Evidence from Twenty-Five Major Markets in the 1990s". National Bureau of Economic Research Working Paper No. 9874, July (Cambridge MA: NBER).
10. Danzon, P.M., and Furukawa, M.F., 2003, "Prices and Availability of Pharmaceuticals: Evidence from Nine Countries, " Health Affairs Web Exclusive, October 29, http://content.healthaffairs.org/cgi/content/full/hlthaff.w3.521v1/DC1.
11. Deardoff A.V., 1992, "Welfare Effects of World Patent Protection, " Economica, 59(233) February, 33-51.
12. DiMasi, J.A., Hansen, R.W., and Grabowski, H.G., 2003, "The Price of Innovation: New Estimates of Drug Development Costs, " Journal of Health Economics, 22(2) March, 151-85.
13. Diwan, I., and Rodrik, D., 1991, "Patents, Appropriate Technology and North-South Trade, " Journal of International Economics, 30(1-2) February, 27-47.
14. Ekelund, M., and Persson, B., 2003, "Pharmaceutical Pricing in a Regulated Market, " The Review of Economics and Statistics, 85(2) May, 298-306.
15. Ellison, S. F., Cockburn, I., Griliches, Z, and Hausman, J., 1997, "Characteristics of Demand for Pharmaceutical Products: An Examination of Four Cephalosporins, " RAND Journal of Economics, 28(3) Autumn, 426-446.
16. Grabowski, H.G., Vernon, J., and DiMasi, J.A., 2002, "Returns on Research and Development for 1990s New Drug Introductions, " Pharmacoeconomics, 20(15) Supp. 3, 11-29.
17. Green, W.H., 2000, Econometric Analysis, 4th ed. (Upper Saddle River NJ: Prentice Hall).
18. Helpman, E., 1993, "Innovation, Imitation and Intellectual Property Rights, " Econometrica, 61(6) November, 1247-1280.
19. IMS Retail Drug Monitor 2004, 2004 (August), www.imshealth.com/vgn/images/portal/cit-40000873/58/22/52756740IMS-DRUGMON-MAY04.pdf.
20. Lanjouw, J.O., and Cockburn, I.M., 2001, "New Pills for Poor People? Empirical Evidence after GATT, " World Development, 29(2) February, 265-289.
21. Lichtenberg, F., 2001a, "The Allocation of Publicly Funded Biomedical Research, " in Medical Care Output and Productivity, Studies in Income and Wealth, Volume 62, ed. by Ernst Berndt and David Cutler (Chicago: University of Chicago Press), 565-89.
22. Danzon, P.M., 2001b, "The Benefits and Costs of Newer Drugs: Evidence from the 1996 Medical Expenditure Panel Survey, " National Bureau of Economic Research Working Paper No. 8147(Cambridge MA: NBER) March.
23. Danzon, P.M., Philipson, J. P., 2002, "The Dual Effects of Intellectual Property Regulations:-Within and Between-Patent Competition in the US Pharmaceutical Industry, " National Bureau of Economic Research Working Paper No. 9303(Cambridge MA: NBER) October.
24. Danzon, P.M., 2004, "The Expanding Pharmaceutical Arsenal in the War on Cancer, " National Bureau of Economic Research Working Paper No. 10328 (Cambridge MA: NBER) February.
25. Danzon, P.M., 2005, "Pharmaceutical innovation and the burden of disease in developing and developed countries, " Journal of Medicine and Philosophy 30(6), December 2005.
26. Lu, Z.J., Comanor, W.S., 1998, "Strategic Pricing of New Pharmaceuticals, " Review of Economics and Statistics, 80(1) February, 108-118.
27. Manheimer, E., and Anderson, D., 2002, "Survey of public information about ongoing clinical trials funded by industry: evaluation of completeness and accessibility, " British Medical Journal 325 (7363) September, 528-531.
28. Mathers, C.D., Bernard, C., Iburg, K., Inoue, M., Ma Fat, D., Shibuya, K., Stein, C., and Tomijima, N., 2003, "The Global Burden of Disease in 2002: data sources, methods and results." Geneva, World Health Organization (GPE Discussion Paper No. 54). Available at www.who.int/evidence.
29. Murphy, K.M., Topel, R.H., 2003, "The Economic Value of Medical Research, " in Measuring the Gains from Medical research: An Economic Approach, " Murphy and Topel, eds., (Chicago: University of Chicago Press).
30. Rudholm, N., 2003, "Competition and Substitutability in the Swedish Pharmaceuticals Market, " Applied Economics, 35(14) September, 1609-1617.
31. Scherer, F.M., 2002, "A Note on Global Welfare in Pharmaceutical Patenting, " Federal Reserve Bank of Philadelphia Working Paper No 03-11.
32. Scherer, F.M., and Watal, J., 2002, "Post-TRIPS Options for Access to Patented Medicines in Developing Nations." WHO Hosjbor Conference Background Paper.
33. Till, J.E., Phillips, R.A., and Jadad, A.R., 2003, "Finding Canadian cancer clinical trials on the Internet: An exploratory evaluation of online resources, " Canadian Medical Association Journal, 168 (9) April, 1127-1129.
34. U.S. General Accounting Office, 1992, "Prescription Drugs: Companies Typically Charge More in the United States than in Canada." GAO-HRD-92-110. Washington, D.C.
35. U.S. General Accounting Office, 1994, "Prescription Drugs: Companies Typically Charge More in the United States than in the United Kingdom." GAO/HEHS-94-29. Washington, D.C.
36. U.S. House of Representatives, Committee on Government Reform and Oversight, Minority Staff Report, 1998, Prescription Drug Pricing in the 1st Congressional District in Maine: An International Price Comparison, October 24.
37. Wiggins, N., and Maness, R., 2004, "Price Competition in Pharmaceuticals: The Case of Anti-Infectives, " Economic Inquiry, 42(2) April, 247-263.